

Curriculum Vitae

Name: PAPADIMITRIOU, Evangelia

Date of birth: August 20, 1967

Place of birth: Piraeus, Greece

Nationality: Greek

Address: Agias Kuriakis 30, GR26443 Patras, Greece

Tel/FAX: 0030 2610 962336

E-mail: epapad@upatras.gr

EDUCATION:

University: School of Pharmacy, University of Patras, Patras, Greece; 1985-1989. Degree: B. Pharm

Graduate: Department of Pharmacology, School of Medicine, University of Patras, Patras, Greece; 1990-1994; Degree: Ph.D. in Pharmacology

Postdoctoral: School of Medicine, University of Patras, Patras, Greece; 1994-1995
School of Natural Sciences, University of Patras, Patras, Greece; 1996
School of Medicine, University of Patras, Patras, Greece; 1997-1998

ACADEMIC APPOINTMENTS:

1991-1994: Research Assistant at the University of Wisconsin Medical School, Milwaukee Clinical Campus, Wisconsin, U.S.A.

1995-1997: Assistant Professor of Pharmacology at the Department of Nursing, Faculty of Professions of Health and Providence, Higher technological and Educational Institute of Patras, Greece.

1998-2003: Lecturer of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2003-2009: Assistant Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2009-2015: Associate Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

2015-present: Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.

January 2015: Visiting Professor at the Academic Unit of Orthopaedic and Trauma Surgery, University of Leeds, UK.

ACADEMIC ACTIVITIES:

1999-2000 &

2001-2004: Examiner of Pharmacology for candidate post-graduate fellows of the State Scholarships Foundation.

2000-present: Reviewer of research papers for Carcinogenesis, Journal of Vascular Research, Vascular Pharmacology, Evidence Based Complementary and Alternative Medicine, Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research and

Clinical Oncology, BMC Cardiovascular Disorders, Arthritis and Rheumatism, Cancer Letters, Biochemical Pharmacology, Medicinal Research Reviews, Cell Biology International, Biopolymers, Archives of Biochemistry & Biophysics, Connective Tissue Research, Cellular and Molecular Biology Letters, Arthritis Research and Therapy, Journal of Peptide Science, Expert Review of Anticancer Therapy, Cancer Chemotherapy and Pharmacology, Current Cancer Drug Targets, Mini Reviews in Medicinal Chemistry, Life Sciences, Molecular Biology Reports, International Journal of Radiation Biology, Journal of Angiogenesis Research, Journal of Biological Chemistry, Journal of Molecular and Cellular Cardiology, British Journal of Pharmacology, Expert Review in Anticancer Therapy, Chemotherapy, Journal of Cellular Biochemistry, Cancer Epidemiology, Biomarkers and Prevention, Journal of Biomedical Nanotechnology, Current Medicinal Chemistry, Basic & Clinical Pharmacology & Toxicology, Expert Opinion on Therapeutic Targets, European Journal of Medicinal Chemistry, International Immunopharmacology, British Journal of Medicine and Medical Research, Current Pharmaceutical Design, Cell Death and Disease, Plos One, British Journal of Pharmaceutical Research, Environmental Toxicology and Pharmacology, Nanomedicine: Nanotechnology, Biology, and Medicine, Science Signalling, The FEBS Journal, Oncotarget, Cytokine, Biomaterials, Scientific Reports.

- 2000-present: Member of the scientific and/or organizing committees of numerous national and international conferences or workshops.
- 2002-present: Reviewer of National (*General Secretariat for Research and Technology, Ministry of Education and Religions, Hellenic Foundation for Research and Innovation*) and International (*Association for International Cancer Research, Dutch Cancer Society, Czech Science Foundation, French National Research Agency, H2020 Marie Skłodowska-Curie Action Innovative Training Networks, Italian Ministry of Education, Universities and Research, Israel Science Foundation*) Research Grants.
- 2002-present: Scientific director of 5 ERASMUS bilateral agreements.
- 2005-present: Member of 9 scientific societies (*Hellenic Society of Pharmacology, Hellenic Society of Biochemistry and Molecular Biology, Hellenic Society for Studying Bone Metabolism, American Society of Biochemistry and Molecular Biology, European Cytokine Network, European Calcified Tissue Society, American Society for Pharmacology and Experimental Therapeutics, British Society of Pharmacology, European Vascular Biology Organization*).
- 2010-present: External evaluator of medicinal products for human use for the National Organization for Medicines.
- 2011-present: External evaluator of candidate post-graduate students' applications for fellowships from the State Scholarships Foundation.
- 2012- 2018: Member of the special interdepartmental (Chemistry, Pharmacy, Medicine) committee of the postgraduate studies program in Medicinal Chemistry: Drug Design and Development, University of Patras, Greece.
- 2014-present: Scientific Director of the postgraduate studies program of the Department of Pharmacy, School of Health Sciences, University of Patras, Greece.
- 2016-2019: Member of the Hellenic Central Board of Health (Ministry of Health).
- 2018-present: Evaluator of studies program or of faculty members at National (Hellenic Universities) and International (The University of Jordan, University of Nicosia, University of Helsinki) Institutions.

ADMINISTRATIVE APPOINTMENTS AND OTHER ACTIVITIES:

- 1999-present: Member of the General Assembly and several committees of the Department of Pharmacy, University of Patras.
- 2007-2010: Treasurer of the Hellenic Society of Pharmacology.
- 2006-2007: Member of the board of the Hellenic Society of Biochemistry and Molecular Biology.
- 2010-2013: Chairman of the Committee for listing reimbursed medicinal products in Greece.
- 2011-2012: Alternate member of the Senate of the University of Patras.
- 2014- present: Alternate member of the Erasmus and the Erasmus+/International Credit Mobility committees of the University of Patras.
- 2014- present: Director of the Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras.

HONORS AND AWARDS:

National Scholarship Foundation fellowship for distinction in pre-graduate studies and postgraduate fellowship as a Ph.D. student

20 prizes to participate in conferences/workshops or for best presentations

Invited speaker in 48 conferences/meetings/seminars (21 national and 27 international)

Recipient of 27 research grants (18 as a PI and 9 as collaborating group leader)

EDITORIAL BOARD MEMBER:

Recent Patents on Anti-Cancer Drug Discovery (2007-present)

World Journal of Biological Chemistry (2010-2014)

ISRN Vascular Medicine (2011-2014)

Heliyon's (2016-present)

RESEARCH PROJECTS

Research Interests:

- Angiogenesis and tumor growth *in vivo* and *in vitro*. Pharmacological studies on the mechanisms involved, and evaluation of new compounds or nanoparticles for their anti-angiogenic and anti-tumor activity.
- The biological actions of the heparin-binding growth factor pleiotrophin. Effects on endothelial cell functions, angiogenesis, tumor growth and metastasis, bone cell biology. Signaling and receptors identification. Structure-function studies.
- The role of receptor RPTPbeta/zeta in angiogenesis and tumor growth. Structure-function studies.

Active Grants

“Study of the role of moesin in endothelial and cancer cell migration for the emergence of a new pharmacological target and therapeutic approaches”. Scholarship from Andreas Mentzelopoulos Institution, 2020-2022. Supervisor.

"Study of the involvement of pleiotrophin in bone remodeling, aiming at identifying new therapeutic targets and/or approaches", Operational Program "Human Resources Development, Education and Lifelong Learning" - Support for researchers with emphasis on new researchers - Cycle B, 2019-2020, PI

State Scholarship Foundation, Strengthening human research potential through doctoral research. "Investigation of the role of anaplastic lymphoma kinase in angiogenesis, as a target for therapeutic interventions". 2018-2021, PI.

State Scholarship Foundation, Strengthening human research potential through doctoral research. "Investigation of the role of ribosomes and protein synthesis in endothelial and cancer cell migration, aiming to identify novel anticancer pharmacological interventions". 2018-2021, PI.

Completed Grants

Private Funding: "A Novel and Effective Treatment of Type 2 Diabetes (T2D)", 2017-2020, PI

State Scholarship Foundation, Strengthening human research potential through doctoral research. "Investigation of the role of pleiotrophin and its receptor with tyrosine phosphatase activity in tumor angiogenesis in vivo". 2016-2019, PI.

State Scholarship Foundation, Strengthening human research potential through doctoral research. "Study of the mechanisms through which the receptor protein tyrosine phosphatase β/ζ regulates cancer growth and angiogenesis". 2016-2019, PI.

State Scholarship Foundation, Strengthening human research potential through doctoral research. "Investigation of the role of pleiotrophin and its receptor with tyrosine phosphatase activity in normal angiogenesis and cardiovascular function in vivo". 2016-2019, PI.

Marie Curie Intra European Fellowship (IEF) - "Understanding tumor resistance: Receptors and signaling pathways that can lead the race against tumor angiogenesis", 2015-2019, FP7 (People), PI

"Elucidation of the pleiotrophin signaling pathways that are related to endothelial cell migration", 2011-2015, Greek Ministry of Education, PI

"Development of Multi-Functional Magnetic Nanoparticles for Targeted Delivery of Anticancer Drugs", 2012-2015, Greek Ministry of Education, Collaborating group leader

Excellence for Postgraduate studies in Greece - Siemens Program, 2013-2014, PI

"Role of pleiotrophin in osteoarthritis". Hellenic Society for studying Bone Metabolism, 2012-2013, Co-investigator

"Identification of proteins that interact with pleiotrophin and elucidation of their function". Greek Ministry of Education, 09/10-06/2013, PI

"Preliminary investigation of the role of the growth factor pleiotrophin as a therapeutic target for osteoporosis by using osteoblast-like cells in vitro". Hellenic Society for studying Bone Metabolism, 2009-2010, PI

"Structure-function studies for the growth factor pleiotrophin, in order to determine region(s) of the molecule with anti-tumor activity". Greek Secretariat for Research and Technology, 06/05 - 12/08, PI

"Role of pleiotrophin in the therapy of glioblastomas". Greek Ministry of Education, 01/05 - 12/07, PI

"Mechanisms of pleiotrophin-induced cancer angiogenesis". Empeirikion Foundation, 09/04 - 09/06, PI

"Mechanisms of action of pleiotrophin in the growth and angiogenesis of glioblastomas". Greek Ministry of Education, 11/02 - 03/06, PI

"Study of the role of the growth factor HARP in human prostate pathophysiology". Greek Ministry of Education, 11/02 - 12/05, Co-investigator

“The role of pleiotrophin in angiogenesis. Structure-function studies”. University of Patras Research Committee, 11/02 - 10/05, PI

“Study of the role of the growth factor HARP in human prostate cancer”, Central Board of Health, Ministry of Health, Greece, 01/01 - 12/02, Co-investigator

"Use of recombinant and synthetic peptides to define biologically active pleiotrophin peptides", Empeirikion Foundation, 06/01 - 06/03, Co-investigator

“Study of the mechanisms through which amifostine protects chorioallantoic membrane blood vessels from ionizing radiation”. University of Patras Research Committee, 11/00 - 10/03, Co-investigator

“Role of heat shock proteins in programmed cell death”, Greek Secretariat for Research and Technology, 01/00 - 06/01, Co-investigator

“Study of the actions of the growth factor HARP in endothelial cells”, University of Patras Research Committee, 10/98 - 09/01, Co-investigator

“Study of the mechanisms through which X-rays inhibit angiogenesis in order to improve their therapeutic use in oncology”, University of Patras Research Committee, 10/98 - 09/01, PI

PATENTS

Papadimitriou E, Kastana P, Ntenekou D (2020) Methods for determining prognosis of a subject with lung adenocarcinoma and responsiveness to treatment. Hellenic Industrial Property Organization Patent Application No. 20200100138/17.03.2020.

PUBLICATIONS (* *indicates correspondence*)

In peer reviewed journals

April 2020: Scopus: >2110 citations, h-index: 28
Google Scholar: >2975 citations, h-index: 33, i10-index: 67

1. Karakioulakis G, **Papadimitriou E**, Missirlis E, Maragoudakis ME. Effect of bivalent metal ions on collagenase from *Clostridium histolyticum*. *Biochemistry International* 34: 397-404, 1991.
2. **Papadimitriou E**, Lelkes PI. Measurement of cell numbers in microtiter culture plates using the fluorescent dye Hoechst 33258. *J Immunol Meth* 162: 41-45, 1993.
3. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes P. I. Time-course and quantitation of extracellular matrix maturation in the chick chorioallantoic membrane and in cultured endothelial cells. *Endothelium* 1: 207-219, 1993.
4. **Papadimitriou E**, Manolopoulos VG, Hayman GT, Maragoudakis ME, Unsworth BR, Fenton JW, Lelkes PI. Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. *Am J Physiol* 272 (*Cell Physiol*.41): C1112-C1122, 1997.
5. **Papadimitriou E**, Mintzas A, Skoutari M, Dimitracopoulos G, Anastassiou ED. Cholera toxin stimulates human B-cell DR antigen biosynthesis at the level of translation. *Cell Immunol* 180: 176-184, 1997.
6. **Papadimitriou E**, Kritikou D, Mavroidis M, Zacharopoulou A, Mintzas A. The Heat Shock 70 Gene Family in the Mediterranean Fruit Fly *Ceratitis capitata*. *Insect Mol Biol* 7: 279-290, 1998.
7. Pipili-Synetos E, **Papadimitriou E***, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells *in vitro*. *Br J Pharmacol*, 125: 1252-1257, 1998.
8. Pipili-Synetos E, Kritikou S, **Papadimitriou E**, Athanassiadou A, Flordellis C, Maragoudakis ME. Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. *Br J Pharmacol*, 129: 207-213, 2000.

9. **Papadimitriou E**, Antimisiaris S. Interactions of PC:Chol and PS:Chol liposomes with human cells *in vitro*: Qualitative and quantitative fluorescence studies. *J Drug Target* 8: 335-351, 2000.
10. **Papadimitriou E**, Heroult M, Courty J, Polykratis A, Stergiou C, Katsoris P. Endothelial cell proliferation induced by HARP: implication of N or C terminal peptides. *Biochem Biophys Res Commun* 274: 242-248, 2000.
11. **Papadimitriou E**, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P. HARP induces angiogenesis *in vivo* and *in vitro*: Implication of N or C terminal peptides. *Biochem Biophys Res Commun* 282: 306-313, 2001.
12. **Papadimitriou E**, Maragoudakis ME, Waters C, Manolopoulos VG, Unsworth BR, Lelkes PI. Regulation of extracellular matrix protein deposition and MMP-2 secretion in cultured endothelial cells. *Endothelium* 8: 243-253, 2001.
13. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S, **Papadimitriou E***. X rays modulate extracellular matrix *in vivo*. *Int J Cancer* 94: 690-698, 2001.
14. Kallinteri P, **Papadimitriou E**, Antimisiaris S. Uptake of liposomes which incorporate a glycopeptide fraction of asialofetuin by HepG2 cells. *J Lipos Res* 11: 175-193, 2001.
15. Gortzi O, **Papadimitriou E**, Kontogiannis CG, Antimisiaris SG, Ioannou P. Arsonoliposomes: a novel class of arsenic containing liposomes: Effect of palmitoyl-arsenolipid containing liposomes on the viability of cancer and normal cells in culture. *Pharm Res* 19: 79-86, 2002.
16. Giannopoulou E, Katsoris P, Polytarchou C, **Papadimitriou E***. Nitration of cytoskeletal proteins in the chicken embryo chorioallantoic membrane. *Arch Biochem Biophys* 400: 188-198, 2002.
17. Giannopoulou E, Katsoris P, Parthymou A, Kardamakis D, **Papadimitriou E***. Amifostine protects blood vessels from the effects of ionizing radiation. *Anticancer Res* 22: 2821-2826, 2002.
18. Giannopoulou E, Katsoris P, Kardamakis D, **Papadimitriou E***. Amifostine inhibits angiogenesis *in vivo*. *J Pharmacol Exp Ther* 304: 729-737, 2003.
19. Lawrence F, Liu J-M, Kovacevic M, Bignon J, Meric P, **Papadimitriou E**, Lallemand J-Y, Katsoris P, Potier P, Fromes Y, Wdzieczak-Bakala J. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis *in vitro* and *in vivo*. *Blood* 101: 3014-3020, 2003.
20. Gortzi O, Antimisiaris SG, Klepetsanis P, **Papadimitriou E**, Ioannou PV. Arsonoliposomes: Effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture. *Eur J Pharm Sci* 18: 175-183, 2003.
21. Hatziapostolou M, Katsoris P, **Papadimitriou E***. Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis. *Eur J Pharmacol* 460: 1-8, 2003.
22. Koletsis E, Chatzimichalis A, Fotopoulos V, Kokkinis K, **Papadimitriou E**, Tiniakos D, Marinos E, Bellenis I, Dougenis D. Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology. *Exp Biol Med (Maywood)*, 228: 540-545, 2003.
23. Giannopoulou E, **Papadimitriou E***. Amifostine has antiangiogenic properties *in vitro* by changing the redox status of human endothelial cells. *Free Radical Res* 37: 1191-1199, 2003.
24. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, **Papadimitriou E**, Plouet J, Courty J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. *Oncogene*, 23: 1745-1753, 2004.
25. Polykratis A, Delbe J, Courty J, **Papadimitriou E***, Katsoris P. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. *Int J Biochem Cell Biol*, 36: 1964-1976, 2004.

26. Parthymou A, Kardamakis D, Pavlopoulos G, **Papadimitriou E***. Irradiated C6 glioma cells induce angiogenesis *in vivo* and activate endothelial cells *in vitro*. *Int J Cancer* 110: 807-814, 2004.
27. Polytarchou C, **Papadimitriou E***. Antioxidants inhibit angiogenesis *in vivo* through down-regulation of nitric oxide synthase expression and activity. *Free Radical Res* 38: 501-508, 2004.
28. Loutrari H, Hatziapostolou M, Skouridou V, **Papadimitriou E**, Roussos C, Kolisis F, Papapetropoulos A. Perillyl alcohol inhibits angiogenesis *in vitro* and *in vivo*. *J Pharmacol Exp Ther* 311: 568-575, 2004.
29. Polytarchou C, Gligoris T, Kardamakis D, Kotsaki E, **Papadimitriou E***. X-rays affect the expression of genes involved in angiogenesis. *Anticancer Res*, 24: 2941-2945, 2004.
30. **Papadimitriou E***, Polykratis A, Hatziapostolou M, Parthymou A, Polytarchou C, Mikelis C. Heparin Affin Regulatory Peptide: A new target for tumour therapy? *Curr Cancer Drug Targets* 4: 471-482, 2004.
31. Arsenou E, **Papadimitriou E**, Kliafa E, Hountala M, Nikolaropoulos S. Effects of retinoic acid steroidal analogues on human leukemic HL60 cells proliferation *in vitro* and on angiogenesis *in vivo*. *Anti-Cancer Drugs* 16: 151-158, 2005.
32. Polytarchou C, **Papadimitriou E***. Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. *Eur J Pharmacol* 510: 31-38, 2005.
33. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, **Papadimitriou E***. Heparin Affin Regulatory Peptide is a key player in prostate cancer cell growth and angiogenicity. *Prostate* 65: 151-158, 2005.
34. Polykratis A, Katsoris P, Courty J, **Papadimitriou E***. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. *J Biol Chem* 280: 22454-22461, 2005.
35. Polytarchou C, Hatziapostolou M, **Papadimitriou E***. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. *J Biol Chem* 280: 40428-40435, 2005.
36. Polytarchou C, Kardamakis D, Katsoris P, **Papadimitriou E***. Antioxidants modify the effect of X rays on blood vessels. *Anticancer Res* 26: 3043-3047, 2006.
37. Kokolakis G, Mikelis C, **Papadimitriou E**, Courty J, Karetsou E, Katsoris P. Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells. *In vivo* 20: 629-635, 2006.
38. Pyriohou A, Beis D, Koika V, Potytarchou C, **Papadimitriou E**, Zhou Z, Papapetropoulos A. Soluble guanylyl cyclase activation promotes angiogenesis. *J Pharmacol Exp Ther* 319: 663-671, 2006.
39. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, **Papadimitriou E***. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. *J Biol Chem* 281:32217-32226, 2006.
40. Gryparis E, Hatziapostolou M, **Papadimitriou E**, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. *Eur J Pharm Biopharm* 67: 1-8, 2007.
41. Mikelis C, Koutsoumpa M, **Papadimitriou E***. Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. *Recent Patents on Anti-Cancer Drug Discovery* 2: 175-186, 2007.
42. Parthymou A, Lambropoulou E, Mikelis C, Drosou G, **Papadimitriou E***. Heparin affin regulatory peptide/pleiotrophin interacts with vascular endothelial growth factor and negatively affects tumor growth and angiogenesis induced by glioma cells. *Eur J Cell Biol* 87: 17-29, 2008.

43. Fousteris MA, Vlachopoulos G, Koutsourea A, Manioudaki M, Lampropoulou E, **Papadimitriou E**, Spyroulias G, Nikolaropoulos SS. Pyrrolo[2,3-a]carbazoles as potential CDK1 inhibitors. Synthesis, preliminary evaluation and binding properties through docking simulations. *J Med Chem* 51: 1048-1052, 2008.
44. Mikelis C, **Papadimitriou E***. Heparin-binding protein pleiotrophin: An important player in the angiogenic process. *Connect Tissue Res* 49: 149-152, 2008.
45. **Papadimitriou E**, Koliakos G, Karamanos N. Biochemistry and Molecular Biology in Greece: History and perspectives. *IUBMB Life* 60: 250-253, 2008.
46. Polytarchou C, Hatzia Apostolou M, Poimenidi E, Mikelis C, Papadopoulou A, Parthymou A, **Papadimitriou E***. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase β/ζ . *Int J Cancer* 124: 1785-1793, 2009.
47. Koutsoumpa M, Hatzia Apostolou M, Mikelis C, Koolwijk P, **Papadimitriou E***. Aprotinin stimulates angiogenesis and human endothelial cell migration through through the growth factor pleiotrophin and its receptor protein tyrosine phosphatase β/ζ . *Eur J Pharmacol* 602: 245-249, 2009.
48. Poimenidi E, Hatzia Apostolou M, **Papadimitriou E***. Serum stimulates pleiotrophin gene expression and secretion in an AP-1 dependent manner in human endothelial and glioblastoma cells. *Anticancer Res* 29: 349-354, 2009.
49. Mikelis C, Sfaelou E, Koutsoumpa M, Kieffer N, **Papadimitriou E***. Integrin $\alpha_v\beta_3$ is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase β/ζ . *FASEB J* 23: 1459-1469, 2009.
50. Sadikoglou E, Magoulas G, Theodoropoulou C, Athanassopoulos C, Giannopoulou E, Theodorakopoulou O, Drainas D, Papaioannou D*, **Papadimitriou E.*** Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth. *Eur J Med Chem* 44: 3175-3187, 2009.
51. **Papadimitriou E***, Mikelis C, Lampropoulou E, Koutsoumpa M, Theochari K, Tsirmoula S, Theodoropoulou C, Lamprou M, Sfaelou E, Vourtsis D, Mpountouris P. Role of pleiotrophin in tumor growth and angiogenesis *Eur Cytokine Netw* 20: 180-190, 2009.
52. Mattheolabakis G, Lagoumintzis G, Panagi Z, **Papadimitriou E**, Partidos CD, Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: Induction of immune responses. *Int J Pharm* 385: 187-193, 2010.
53. Friligou I, **Papadimitriou E**, Gatos D, Matsoukas J, Tselios T. Microwave-assisted solid-phase peptide synthesis of the 60-110 domain of human pleiotrophin (hPTN) on 2-chlorotriptyl resin. *Amino Acids* 40: 1431-1440, 2011.
54. Mikelis C, Lamprou M, Koutsoumpa M, Koutsoubas AG, Spyranti Z, Zompra AA, Spiliopoulos N, Vradis AA, Katsoris P, Spyroulias GA, Cordopatis P, Courty J, **Papadimitriou E***. A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro. *J Cell Biochem* 112: 1532-1543, 2011.
55. Lampropoulou E, Manioudaki M, Fousteris M, Koutsourea A, Nikolaropoulos S and **Papadimitriou E***. Pyrrolo[2,3- α]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo. *Biomed Pharmacother* 65: 142-150, 2011.
56. Kouroufexi A, Theophanous-Kitiri S, Polykarpou G, Markou G, **Papadimitriou E**. Clinical evaluation of lenograstim use in the Bank of Cyprus Oncology Centre. *European Journal of Oncology Pharmacy (EJOP)* 5: 31-33, 2011.
57. Koutsoumpa M, Drosou G, Mikelis C, Theochari K, Vourtsis D, Katsoris P, Giannopoulou E, Courty J, Petrou C, Magafa V, Cordopatis P, **Papadimitriou E***. Pleiotrophin expression and role in physiological angiogenesis in vivo: Potential involvement of nucleolin. *Vascular Cell* 4: 4, 2012.

58. Tsirmoula S, Dimas K, Hatziapostolou M, Lamprou M, Ravazoula P, **Papadimitriou E***. Implication of pleiotrophin in human prostate PC3 cancer cell growth in vivo. *Cancer Sci* 103:1826-32, 2012.
59. Pantazaka E, **Papadimitriou E***. PTN (pleiotrophin). *Atlas Genet Cytogenet Oncol Haematol* 16: 821-837, 2012.
60. Vourtsis D, Giannou T, Sadikoglou E, Theodorakopoulou O, Sarrou H, Magoulas G, Athanassopoulos CM, Drainas D, Papaioannou D, and **Papadimitriou E***. Effect of all-trans-retinoic acid and its conjugate with spermine on human endothelial and prostate cancer cell growth in vitro and angiogenesis in vivo. *Eur J Pharmacol* 698: 122-130, 2013.
61. Kaspiris A, Mikelis C, Heroult M, Khaldi L, Grivas TB, Kouvaras I, Dangas S, Vasiliadis E, Lioté F, Courty J, **Papadimitriou E***. Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis. *Joint Bone Spine*, 80: 407-413, 2013.
62. Koutsoumpa M, Polytarchou C, Courty J, Zhang Y, Kieffer N, Mikelis C, Skandalis S, Hellman U, Iliopoulos D, **Papadimitriou E***. Interplay between alpha v beta 3 integrin and nucleolin regulates human endothelial and glioma cell migration. *J Biol Chem* 288: 343-354, 2013.
63. Kaspiris A, Khaldi L, Grivas TB, Vasiliadis E, Kouvaras I, Dagkas S, Chronopoulos E, **Papadimitriou E**. Subchondral cyst development and MMP-1 expression during progression of osteoarthritis: an immunohistochemical study. *Orthop Traumatol Surg Res* 99: 523-529, 2013.
64. Koniari I, Apostolakis E, Diamantopoulos A, Papadaki H, **Papadimitriou E**, Poimenidi E, Karnabatidis D, Karahaliou A, Costaridou L, Papalois A, Siablis D, Dougenis D, Alexopoulos D. Transaortic balloon angioplasty in rabbit thoracic aorta: a novel model of experimental restenosis. *Lipids Health Dis* 13: 33, 2014.
65. Koutsoumpa M, **Papadimitriou E***. Cell surface nucleolin as a target for anti-cancer therapies. *Recent Pat Anticancer Drug Discov* 9: 137-152, 2014.
66. Pantazaka E, **Papadimitriou E***. Chondroitin Sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration. *BBA - General Subjects* 1840: 2643-2650, 2014.
67. Vasiliadis ES, Kaspiris A, Grivas TB, Khaldi L, Lamprou M, Pneumaticos SG, Nikolopoulos K, Korres DS, **Papadimitriou E**. Expression of macrophage elastase (MMP12) in rat tail intervertebral disc and growth plate during degeneration after asymmetric loading. *Bone Joint Res* 3: 273-279, 2014.
68. Lamprou M, Kaspiris A, Panagiotopoulos E, Giannoudis P, **Papadimitriou E***. The role of pleiotrophin in bone repair. *Injury* 45: 1816-1823, 2014.
69. Koutsoumpa M, Poimenidi E, Pantazaka E, Theodoropoulou C, Skoura A, Megalioikonomou V, Kieffer N, Courty J, Mizumoto S, Sugahara K, **Papadimitriou E***. Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor. *Mol Cancer* 14: 19, 2015.
70. Tsirmoula S, Lamprou M, Hatziapostolou M, Kieffer N, **Papadimitriou E***. Pleiotrophin-induced endothelial cell migration is regulated by xanthine oxidase-mediated generation of reactive oxygen species. *Microvasc Res* 98:74-81, 2015.
71. Kaspiris A, Khaldi L, Chronopoulos E, Vasiliadis E, Grivas T, Kouvaras I, Dagkas S, **Papadimitriou E**. Macrophage - specific metalloelastase (MMP - 12) immunoexpression in the osteochondral unit in osteoarthritis correlates with BMI and disease severity. *Pathophysiology* 22: 143-151, 2015.
72. Giannopoulou E, Nikolakopoulos A, Kotsirilou D, Lampropoulou A, Raftopoulou S, **Papadimitriou E**, Theocharis AD, Makatsoris T, Fasseas K, Kalofonos HP. Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. *J Biomed Sci* 22: 98, 2015.

73. Koniari I, Mavrilas D, Papadaki H, **Papadimitriou E**, Poimenidi E, Papalois A, Hahalis G, Xanthopoulou I, Alexopoulos D, Apostolakis E. Simvastatin and ivabradine inhibiting atherosclerosis progression, intimal hyperplasia and peroxynitrite-mediated oxidative stress reduce thoracic aorta's stiffness in hypercholesterolemic rabbits. *J Cardiovasc Pharmacol Ther* 21: 412-422, 2016.
74. Kaspiris A, Chronopoulos E, Grivas TB, Vasiliadis E, Khaldi L, Lamprou M, Lelovas PP, Papaioannou N, Dontas IA, **Papadimitriou E***. Effects of mechanical loading on the expression of pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in a rat spinal deformity model. *Cytokine* 78:7-15, 2016.
75. Poimenidi E, Theodoropoulou C, Koutsioumpa M, Skondra L, Droggiti E, van den Broek M, Koolwijk P, **Papadimitriou E***. Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner. *Vasc Pharmacol* 80:11-19, 2016.
76. Sarigiannis Y, Kolokithas-Ntoukas A, Beziere N, Zbořil R, **Papadimitriou E**, Avgoustakis K, Lamprou M, Medrikova Z, Rousalis E, Ntziachristos V, Bakandritsos A. Synthesis and evaluation of condensed magnetic nanocrystal clusters with in vivo multispectral optoacoustic tomography for tumour targeting. *Biomaterials* 91:128-139, 2016.
77. Tsigkas G, Katsanos K, Apostolakis E, **Papadimitriou E**, Koutsioumpa M, Karnabatidis D, Kagadis GC, Koumoundourou D, Hahalis G, Alexopoulos D. A novel endovascular experimental model for induction of chronic myocardial hypertrophy in rabbits. *Hypertension Res* 39: 840-847, 2016.
78. **Papadimitriou E***, Pantazaka E, Castana P, Tsalios T, Polyzos A, Beis D. Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. *BBA Reviews on Cancer* 1866: 252-265, 2016.
79. Magoulas GE, Tsigkou T, Skondra L, Lamprou M, Tsoukala P, Kokkinogouli V, Pantazaka E, Papaioannou D, Athanassopoulos CM*, **Papadimitriou E***. Synthesis of novel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents. *Bioorg Med Chem* 25: 3756-3767, 2017.
80. Kalamatianos T, Denekou D, Stranjalis G, **Papadimitriou E***. Anaplastic Lymphoma Kinase in glioblastoma: detection/diagnostic methods and therapeutic options. *Recent Pat Anticancer Drug Discov* 13: 209-223, 2018.
81. Lampropoulou E, Logoviti I, Koutsioumpa M, Hatziapostolou M, Polytarchou C, Skandalis SS, Hellman U, Fouteris M, Nikolaropoulos S, Choleva E, Lamprou M, Skoura A, Megalooikonomou V, **Papadimitriou E***. Cyclin-dependent kinase 5 mediates pleiotrophin-induced endothelial cell migration. *Sci Rep* 8: 5893, 2018.
82. Kastana P, Choleva E, Poimenidi E, Karamanos N, Sugahara K, **Papadimitriou E***. Insight into the role of chondroitin sulfate E in angiogenesis. *FEBS J* 286(15):2921-2936, 2019.
83. Kastana P, Zahra FT, Ntenekou D, Katraki-Pavlou S, Beis D, Lionakis MS, Mikelis CM, **Papadimitriou E***. Matrigel Plug Assay for In Vivo Evaluation of Angiogenesis. *Methods Mol Biol* 1952:219-232, 2019.
84. Zahra FT, Choleva E, Sajib MS, **Papadimitriou E**, Mikelis CM. In Vitro Spheroid Sprouting Assay of Angiogenesis. *Methods Mol Biol* 1952:211-218, 2019.
85. Bourika K, Koutras A, Kalofonos H, Vicha A, Tsiata E, **Papadimitriou E**, Avgoustakis K, Panagi Z. Improvement of Chemotherapy Solutions Production Procedure in a Hospital Central Chemotherapy Preparation Unit: A Systematic Risk Assessment to Prevent Avoidable Harm in Cancer Patients. *Clin Med Insights Oncol* 13: 1179554919852933, 2019.
86. Panagi Z, Bountouris P, Skroubis G, **Papadimitriou E**, Skouroliakou M, Kalfarentzos F. A pilot study on the Preoperative and Short-term Postoperative Serum Fat-Soluble Vitamin Levels in Super-obese Patients Undergoing A Biliopancreatic Diversion with Roux-en-Y Gastric Bypass (BPD/RYGBP) Malabsorptive Operation. *EC Pharmacology & Toxicology* 7(7): 535-546, 2019.

87. Mourkogianni E, Karatza A, Vinni E, **Papadimitriou E**, Avgoustakis K, Panagi Z. Assessment and Optimization of Pediatric Total Parenteral Nutrition Preparation Process in a Hospital Pharmacy. *JPEN J Parenter Enteral Nutr* 2020; doi: 10.1002/jpen.1787.
88. Sioriki AA, Gkentzi D, **Papadimitriou E**, Dimitriou G, Karatza A. Vaccinations in infants born preterm: An update. *Curr Pediatr Rev* 2020; doi: 10.2174/1573396316666200116094459.
89. Lamprou M, Kastana P, Kofina F, Tzoupis H, Barboutsi S, Sajib MdS, Koutsoumpa M, Poimenidi E, Zompra A, Tassopoulos D, Choleva E, Tselios T, Mikelis CM, **Papadimitriou E***. Pleiotrophin selectively binds to vascular endothelial growth factor receptor 2 and inhibits or stimulates cell migration depending on $\alpha_v\beta_3$ integrin expression. *Angiogenesis* 2020; submitted in revised form.
90. Cuthbert RJ, Sanjurjo-Rodríguez C, Churchman SE, Lotfy A, Kastana P, Tan HB, McGonagle D, **Papadimitriou E**, Jones E, Giannoudis PV. Regulation of angiogenesis discriminates tissue resident MSCs from effective and defective osteogenic environments. *J Clin Med* 2020; submitted in revised form.
91. Tsirmoula S, Enake K-M, Skondra L, Koutsoumpa M, Kastana P, Mikelis CM, Skandalis S, Skoura A, Megalooikonomou V, Hellman U, **Papadimitriou E***. Interaction of moesin with $\alpha_v\beta_3$ integrin negatively regulates endothelial cell migration. *To be submitted*.
92. Kastana P, Ntenekou D, Marazioti A, Nikou S, Papadaki E, Gonzalo H, Stathopoulos G, Mikelis CM, **Papadimitriou E***. Receptor protein tyrosine phosphatase zeta 1 expression is inversely correlated to lung carcinogenesis and angiogenesis *in vivo*. *In preparation*.
93. Theodorakopoulou O., Tsirmoula S., Hatziapostolou M., Theodoropoulou C., Pantazaka E. and **Papadimitriou E.*** Role of pleiotrophin in the inhibitory effect of all trans retinoic acid on human prostate cancer cell migration. *In preparation*.
94. Lampropoulou E, Parthymou A, Lamprou M, **Papadimitriou E***. cAMP up-regulates PTN expression through protein kinase A and activator protein-1. *In preparation*.

Invited per-reviewed chapters in books

1. Polytarchou C, Hatziapostolou M, **Papadimitriou E***. Endothelial cell migration assays. In: "Angiogenesis assays: A critical appraisal of current techniques", Editors: Carolyn Staton, Claire Lewis and Roy Bicknell, John Wiley and Sons, Ltd, 2006, pages 51-64.
2. Polytarchou C, Hatziapostolou M, Poimenidi E and **Papadimitriou E***. Reactive oxygen species as mediators of angiogenesis signalling. In: "Angiogenesis: Basic Science and Clinical Applications", Editors: Michael E. Maragoudakis and Evangelia Papadimitriou, Transworld Research Network, 2007, pages 213-233.
3. **Papadimitriou E***. Pleiotrophin. In: "Encyclopedia of Cancer" 2nd Edition, pages 2367-2369. Editor: Manfred Schwab, Springer-Verlag, 2008.
4. Koutsoumpa M, **Papadimitriou E***. PG receptors with phosphatase action in cancer and angiogenesis. In: "Extracellular Matrix: Pathobiology and Signalling", Editor: Nikos Karamanos, Walter de Gruyter GmbH & Co. KG, Berlin/Boston, 2012, pages 813-823.
5. **Papadimitriou E***. Pleiotrophin. In: "Encyclopedia of Cancer", doi: 10.1007/978-3-642-27841-9_4621-3. Editor: Manfred Schwab, Springer-Verlag Berlin Heidelberg, 2014.
6. Koutsoumpa M, Choleva E, **Papadimitriou E***. Targeting Cell Surface Nucleolin in Cancer. In: Patent eBook Series "Topics in Anti-Cancer Research", Volume 4, Editors: Atta-ur-Rahman, Khurshid Zaman, Bentham eBooks, 2015, pages 104-155.

Peer-reviewed publications in Greek journals

1. Tziafeta SG, Karamelas NA, Skotsimara P, Korfiati E, **Papadimitriou E**, Skeparni F. Toxicological aspects of sudden and violent deaths in Southwestern Greece: A three-year review (2001-2004). *Hellenic Medical and Pharmaceutical Review II* (2): 33-43, 2005.
2. Karamelas NA, Tziafeta SG, Skotsimara P, Korfiati E, **Papadimitriou E**, Skeparni F. Toxicological aspects of fatal accidents in Southwestern Greece: A three-year experience (2001-2004). *Hellenic Medical and Pharmaceutical Review II* (2): 44-53, 2005.
3. Vomvas D, Mpountouris P, Theodoropoulou X, Dermizioti E, Viha A, **Papadimitriou E**, Kardamakis D. Neutrophils growth factors and radiotherapy. *Forum of Clinical Oncology* 8 (3-4):175-183, 2009.
4. Lamprou M, Koutsioumpa M, Kaspiris A, Vasiliadis E, Kataxaki E, **Papadimitriou E***. The role of pleiotrophin and its receptor RPTP β/ζ in bone pathophysiology. *Ostoun* 22 (4): 188-198, 2011.
5. Chronopoulos E, Kaspiris A, Khaldi L, Vasiliadis E, Kataxaki E, Papaioannou N, **Papadimitriou E**. Monosodium Iodoacetate (MIA) induced experimental osteoarthritis animal model. *Ostoun* 25(1): 6-13, 2014.

Publications in conference book proceedings

1. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes PI. Quantitative analysis of extracellular matrix formation *in vivo* and *in vitro*. In: "Angiogenesis: Molecular Biology, Clinical Aspects", ed. by Maragoudakis ME, Gullino PM, Lelkes PI, Plenum Press, *pps.* 291-305, 1994.
2. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes PI. Expression of SPARC during embryonic development of the chick chorioallantoic membrane. In: "Angiogenesis: Molecular Biology, Clinical Aspects", ed. by Maragoudakis ME, Gullino PM, Lelkes PI, Plenum Press, page 354, 1994.
3. **Papadimitriou E**, Maragoudakis ME, Manolopoulos VG, Unsworth BR, Lelkes PI. Differential regulation of extracellular matrix protein secretion and deposition by cultured endothelial cells. In: "Molecular, Cellular and Clinical aspects of Angiogenesis", ed. by Maragoudakis ME, Plenum Press, page 274, 1996.
4. Papaioannou S, Hatjimichael H, **Papadimitriou E**, Kardamakis D, Demopoulos J. Effects of X-ray irradiation doses and NO synthase modulation on embryonic angiogenesis. In: "Vascular Endothelium: Mechanisms of Cell Signaling", ed. by Catravas J, Callow A and Ryan U, IOS Press, *pps.* 206-208, 1999.
5. Katsoris P, Courty J, Polykratis A, Giannopoulou E, Papaioannou S, **Papadimitriou E**. HARP and endothelium. In: "Vascular Endothelium: Source and Target of Inflammatory Mediators", ed. by Catravas J, Callow A and Ryan U, IOS Press, *pps.* 313-315, 2001.
6. **Papadimitriou E**, Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Papaioannou S. Protective implication of antioxidants in the chick embryo chorioallantoic membrane. In: "Vascular Endothelium: Source and Target of Inflammatory Mediators", ed. by Catravas J, Callow A and Ryan U, IOS Press, *pps.* 332-334, 2001.
7. Polycratis A, **Papadimitriou E**, Courty J, Stergiou C, Papaioannou S, Katsoris P. Biological action of peptides derived from the molecule of the growth factor HARP. In: "2nd Hellenic Forum of Bioactive Peptides", ed. by Cordopatis PA, Typorama, *pps.* 467-473, 2001.
8. **Papadimitriou E**, Polykratis A, Karetsoy E, Courty J, Katsoris P. Use of synthetic peptides for the identification of the biologically active domains of the growth factor HARP. In: "Drug Discovery and Design: Medical Aspects", ed. by Matsoukas J and Mavromoustakos T, IOS Press, *pps.* 251-257, 2002.

9. Polykratis A, **Papadimitriou E**, Mikelis C, Zompra A, Galanis A, Cordopatis P, Courty J, Katsoris P. Synthesis and biological action of two synthetic peptides corresponding to the C-terminal region of HARP In: "3rd Hellenic Forum of Bioactive Peptides", ed. by Cordopatis PA, Manesi-Zoupa E and Pairas G, Typorama, pps. 473-480, 2003.

Cited conference presentations

1. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes PI. Quantitative analysis of extracellular matrix formation *in vivo* and *in vitro*. *32nd Annual Meeting of the American Society for Cell Biology*, Denver, Colorado, USA, December 15-19, 1992. *Mol Biol Cell* 3(Suppl.): 228a, 1992.
2. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes PI. Quantitative analysis of SPARC during embryonic development of the chick chorioallantoic membrane. *FASEB Experimental Biology '93*, New Orleans, Louisiana, USA, March 28-April 1, 1993. *FASEB J* 7: A126, 1993.
3. **Papadimitriou E**, Unsworth BR, Maragoudakis ME, Lelkes PI. Thrombin increases extracellular matrix deposition in cultured endothelial cells by a mechanism independent of its proteolytic activity. *33rd Annual Meeting of the American Society for Cell Biology*, New Orleans, Louisiana, USA, December 11-15, 1993. *Mol Biol Cell Suppl* 4: 1033a, 1993.
4. **Papadimitriou E**, Mintzas A, Skoutari M, Dimitracopoulos G, Anastassiou ED. Cholera toxin stimulates human B-cell DR antigen biosynthesis at the level of translation. *8th European Congress of Clinical Microbiology and Infectious Diseases*, Lausanne, Switzerland, May 25-28, 1997. *Clin Microbiol Infect* 3(Suppl 2): 201, 1997.
5. **Papadimitriou E**, Antimisiaris S. Interactions of PC:chol liposomes with human cells *in vitro*: qualitative and quantitative fluorescence studies. *The 6th liposome research days conference*, Les Embiez, France, May 28-31, 1998. *J Lipos Res* 8: 93-94, 1998.
6. Giannopoulou E, Kardamakis D, Katsoris P, Papaioannou S, **Papadimitriou E**. Amifostine inhibits the antiangiogenic action of X rays. *1st Panhellenic Congress of Pharmacology*, Athens, Greece, February 19-20, 1999. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 13: 78, 1999.
7. Giannopoulou E, Kardamakis D, Katsoris P, Papaioannou S, **Papadimitriou E**. Amifostine inhibits the antiangiogenic action of X rays. *19th Annual Estro Meeting*, Istanbul, Turkey, September 19-23, 2000. *Radiother Oncol* 56(Suppl 1): S183, 2000.
8. Polykratis A, Heroult M, **Papadimitriou E**, Courty J, Katsoris P. Angiostatic activity of HARP peptide generated by plasmin treatment. *International Conference organized and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1653, 2001.
9. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S, **Papadimitriou E**. X-Rays modulate synthesis and degradation of extracellular matrix proteins. *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1634, 2001.
10. Polytarchou C, Katsoris P, Kardamakis D, **Papadimitriou E**. Free radical scavengers alter the anti- angiogenic effect of x rays. *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1654, 2001.
11. Hatziapostolou M, **Papadimitriou E**, Giannopoulou E, Koolwijk P, Katsoris P. Inhibition of plasmin stimulates angiogenesis *in vivo*. *International Conference organised and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1636, 2001.

12. Parthymou A, Katsoris P, Kardamakis D, **Papadimitriou E**. Induction of angiogenesis and tumor progression by irradiated C6 glioma cells on the chick chorioallantoic membrane. *International Conference organized and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1651, 2001.
13. **Papadimitriou E**, Polycratis A, Heroult M, Kokolakis G, Courty J, Katsoris P. HARP is an angiogenic growth factor. *International Conference organized and supported by the International Institute of Anticancer Research: "Invasion and Metastasis"*, Athens, Greece, June 14-17, 2001. *Anticancer Res* 21(3A): 1653, 2001.
14. Parthymou A, Katsoris P, Kardamakis D, **Papadimitriou E**. Induction of angiogenesis and tumour progression by irradiated C6 glioma cells implanted on the chicken embryo chorioallantoic membrane. *ECCO 11 European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. *Eur J Cancer* 37(Suppl 6): S112, 2001.
15. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S, **Papadimitriou E**. X Rays affect the extracellular matrix in a way that favours both normal and tumour-induced angiogenesis. *ECCO 11th European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. *Eur J Cancer* 37(Suppl 6): S111, 2001.
16. **Papadimitriou E**, Polycratis A, Heroult M, Kokolakis G, Courty J, Katsoris P. The angiogenic role of HARP, a novel growth factor. *ECCO 11 European Cancer Conference*, Lisbon, Portugal, October 21-25, 2001. *Eur J Cancer* 37(Suppl 6): S111, 2001.
17. Giannopoulou E, Katsoris P, Parthymou A, Kardamakis D, **Papadimitriou E**. Amifostine protects blood vessels from the effects of X rays and prevents radiation-induced tumor growth and angiogenesis. *2nd Panhellenic Congress of Pharmacology*, Athens, Greece, February 9-10, 2002. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 16: 41, 2002.
18. **Papadimitriou E**, Kokolakis G, Courty J, Heroult M, Katsoris P. Contribution of the growth factor HARP in angiogenesis. *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 17: 67, 2003.
19. Kliafa E, Katsoris P, Arsenou E, Nikolaropoulos S, **Papadimitriou E**. Effect of retinoic acid and its analogues on tumor growth and angiogenesis. *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 17: 102, 2003.
20. Sideris S, Katsoris P, **Papadimitriou E**. HARP, nitric oxide and tumor growth. *3rd Conference on Drug Discovery and Design*, Patras, Greece, March 7-9, 2002. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 17: 106, 2003.
21. **Papadimitriou E**, Polytarchou C, Gligoris T, Kardamakis D, Katsoris P. X rays affect the expression of several genes in a way that favors angiogenesis. *21st Annual ESTRO Meeting*, Prague, Czech Republic, September 17-21, 2002. *Radiother Oncol* 64(Suppl 1): S190, 2002.
22. Giannopoulou E, Katsoris P, Parthymou A, Kardamakis D, **Papadimitriou E**. Amifostine prevents radiation-induced tumor growth. *21st Annual ESTRO Meeting*, Prague, Czech Republic, September 17-21, 2002. *Radiother Oncol* 64(Suppl 1): S190, 2002.
23. Polykratis A, Mikelis C, Katsoris P, Courty J, Zompra A, Cordopatis P, **Papadimitriou E**. HARP domains with different activity on angiogenesis. *4th Conference on Drug Design and Development*, Patras, Greece, March 13-14, 2003. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 17: 85, 2003.
24. Parthymou A, Giannopoulou E, Polytarchou C, Hatziapostolou M, Katsoris P, Kardamakis D, **Papadimitriou E**. Induction of angiogenesis by irradiation. *2nd International Conference on Translational Research and Preclinical Strategies in Radiation Oncology*, Lugano, Switzerland, March 16-19, 2003. *Int J Rad Oncol Biol Phys* 55: 504, 2003.

25. Polykratis A, **Papadimitriou E**, Courty J, Katsoris P. Identification of HARP domains with potential activity on angiogenesis *in vitro*. *11th Panhellenic Pharmaceutical Congress*, Athens, Greece, March 29-31, 2003. *Eur J Drug Metab Pharmacokinet* 28: 22, 2003.
26. Giannopoulou E, **Papadimitriou E**. Effect of amifostine on angiogenesis. *11th Panhellenic Pharmaceutical Congress*, Athens, Greece, March 29-31, 2003. *Eur J Drug Metab Pharmacokinet* 28: 22, 2003.
27. Giannopoulou E, **Papadimitriou E**. Amifostine and endothelial cell functions. *SFRR-Europe Meeting 2003 "Free Radicals and Oxidative Stress: Chemistry, Biochemistry and Pathophysiological Implications"*, Ioannina, Greece, June 26-29, 2003. *Free Radical Res* 37: 92, 2003.
28. Liu JM, Bignon JS, Lawrence F, Meric P, Kovacevic M, **Papadimitriou E**, Katsoris P, Fromes Y, Wdzieczak-Bakala J. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, controls normal and pathological angiogenesis. *32nd Annual Meeting, International Society for Experimental Hematology*, Paris, France, July 5-8, 2003. *Exp Hematol* 31: 215, 2003.
29. Polykratis A, **Papadimitriou E**, Delbe J, Courty J, Katsoris P. HARP peptides modulate the *in vitro* angiogenic activity of VEGF. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. *Eur J Cancer Suppl* 1(5): S178, 2003.
30. Giannopoulou E, Kardamakis D, **Papadimitriou E**. Amifostine modulates endothelial cell proliferation and migration. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. *Eur J Cancer Suppl* 1(5): S178, 2003.
31. Hountala M, Arsenou E, Nikolaropoulos S, Hatzia Apostolou M, **Papadimitriou E**. Effect of retinoic acid analogue on tumor growth and angiogenesis. *ECCO 12 - The European Cancer Conference*, Copenhagen, Denmark, September 21-25, 2003. *Eur J Cancer Suppl* 1(5): S298, 2003.
32. Polytarchou C, **Papadimitriou E**. Reactive oxygen species are implicated in physiological angiogenesis *in vivo* and *in vitro*. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 28-29, 2004.
33. Hatzia Apostolou M, **Papadimitriou E**. Effect of HARP on the growth of human prostate cancer cells. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 121-122, 2004.
34. Karampelas NA, Tziafeta SG, **Papadimitriou E**, Skeparni F. Toxicological aspects of fatal accidents in south-western Greece: A three-year experience (2001-2003). *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 126-127, 2004.
35. Mikelis C, Polykratis A, Zompra A, Cordopatis P, Katsoris P, Courty J, **Papadimitriou E**. A synthetic peptide that corresponds to the C-terminal region of HARP inhibits angiogenesis *in vivo* and *in vitro*. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 144-145, 2004.
36. Parthymou A, Kardamakis D, **Papadimitriou E**. Irradiation of C6 glioma cells with X rays increases the expression of angiogenic genes and their angiogenic potential *in vitro* and *in vivo*. *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 165-166, 2004.
37. Tziafeta SG, Karampelas NA, **Papadimitriou E**, Skeparni F. Toxicological aspects of sudden and violent deaths in southwestern Greece: A three-year review (2001-2003). *3rd Panhellenic Congress in Pharmacology*, Thessaloniki, Greece, February 14-15, 2004. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 18: 184-185, 2004.
38. Mikelis C, Polykratis A, Katsoris P, Zompra A, Cordopatis P, Courty J, **Papadimitriou E**. Antiangiogenic activity of a synthetic peptide that corresponds to the C-terminal region of HARP. *4th Hellenic Forum on Bioactive peptides*, Patras, Greece, April 22-24, 2004. *J Peptide Sci Suppl* 10: H62, 2004.

39. Polykratis A, **Papadimitriou E**, Delbe J, Courty J, Katsoris P. Plasmin generates biologically active peptides of the growth factor HARP. *4th Hellenic Forum on Bioactive peptides*, Patras, Greece, April 22-24, 2004. *J Peptide Sci Suppl* 10: H71, 2004.
40. Parthymou A, Kardamakis D, **Papadimitriou E**. Irradiation of C6 glioma cells with X rays increases the expression of angiogenic genes and their angiogenic potential *in vitro* and *in vivo*. *23rd Annual ESTRO Meeting*, Amsterdam, The Netherlands, October 24-28, 2004. *Radiother Oncol* 73(Suppl 1): S152, 2004.
41. Giannopoulou E, Hatzia Apostolou M, Kardamakis D, **Papadimitriou E**. The effect of X rays on synthesis and deposition of ECM proteins *in vivo*. *23rd Annual ESTRO Meeting*, Amsterdam, The Netherlands, October 24-28, 2004. *Radiother Oncol* 73(Suppl 1): S190, 2004.
42. Parthymou A, **Papadimitriou E**. Role of HARP on the growth of glioblastoma cells. *6th Conference on Drug Design and Development*, Patras, Greece, March 10-12, 2005. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 20: 380, 2006.
43. Polykratis A, Mikelis C, Katsoris P, Courty J, **Papadimitriou E**. Heparin affin regulatory peptide signaling in human endothelial cells. *ECCO 13 -The European Cancer Conference*, Paris, France, October 30 - November 3, 2005. *Eur J Cancer Suppl* 3(2): 54, 2005.
44. Theodorakopoulou O, Hatzia Apostolou M, Polytarchou C, Delbe J, Courty J, **Papadimitriou E**. Effect of retinoic acid on prostate cancer cells *in vitro*. *ECCO 13 - The European Cancer Conference*, Paris, France, October 30 - November 3, 2005. *Eur J Cancer Suppl* 3(2): 55, 2005.
45. Parthymou A, **Papadimitriou E**. Tumor growth and angiogenesis induced by C6 glioma cells are regulated by heparin affin regulatory peptide *in vivo* and *in vitro*. *ECCO 13 - The European Cancer Conference*, Paris, France, October 30 - November 3, 2005. *Eur J Cancer Suppl* 3(2): 59, 2005.
46. Lampropoulou E, Parthymou A, **Papadimitriou E**. Regulation of heparin affin regulatory peptide expression by cAMP in glioma cells. *7th Conference on Drug Design and Development*, Patras, Greece, March 8-11, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 21: 141, 2007.
47. Hatzia Apostolou M, Polytarchou C, **Papadimitriou E**. FGF-2 incites biological activities of human prostate cancer cells via hydrogen peroxide-dependent activation of HARP/pleiotrophin gene. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition, 20: 97, 2006.
48. Drosou G, **Papadimitriou E**. Expression of heparin affin regulatory peptide is essential for angiogenesis *in vivo*. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition, 20: 155, 2006.
49. Lambropoulou E, Parthymou A, **Papadimitriou E**. The role of cAMP in heparin affin regulatory peptide expression in glioma cells. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 20: 241, 2006.
50. Mikelis C, Zompra A, Cordopatis P, **Papadimitriou E**. A synthetic peptide that corresponds to the C-terminal region of HARP inhibits effects of HARP on endothelial cells. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 20: 254, 2006.
51. Poimenidi E, Polykratis A, **Papadimitriou E**. Serum regulates the expression of heparin affin regulatory peptide. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 20: 301, 2006.
52. Theodorakopoulou O, **Papadimitriou E**. Effect of all-trans retinoic acid on prostate cancer cell growth. *4th Panhellenic Congress of Pharmacology*, Patras, Greece, May 19-20, 2006. *Review of Clinical Pharmacology and Pharmacokinetics*, International Edition 20: 331, 2006.

53. Theodorakopoulou O, Hatziapostolou M, **Papadimitriou E**. ATRA's inhibitory effect on prostate cancer cell growth involves HARP expression. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. *FEBS J 273(Suppl 1): 86, 2006.*
54. Lampropoulou E, Parthymou A, Poimenidi E, Giannopoulou E, **Papadimitriou E**. Expression of heparin affin regulatory peptide in glioma cells. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. *FEBS J 273(Suppl 1): 122, 2006.*
55. Polytarchou C, Hatziapostolou M, **Papadimitriou E**. On the interventional role of eNOS in hydrogen peroxide-induced HARP/pleiotrophin up-regulation in endothelial cells. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. *FEBS J 273(Suppl. 1): 149, 2006.*
56. Hatziapostolou M, Polytarchou C, **Papadimitriou E**. FGF-2 stimulatory effects on human prostate cancer cells are mediated by HARP/pleiotrophin: Implication of hydrogen peroxide. *31st FEBS Congress*, Istanbul, Turkey, June 24-29, 2006. *FEBS J 273(Suppl 1): 223, 2006.*
57. Polytarchou C, Hatziapostolou M, Papadopoulou A, Poimenidi E, **Papadimitriou E**. Hydrogen peroxide stimulatory effects on endothelial cells are mediated by heparin affin regulatory peptide: Implication of endothelial nitric oxide synthase. *8th International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Corfu, Greece, June 29 - July 3, 2006. *Endothelium 13: 296, 2006.*
58. Parthymou A, Lampropoulou E, Mikelis C, Drosou G, **Papadimitriou E**. Role of heparin affin regulatory peptide in glioma cell growth and angiogenicity. *8th International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Corfu, Greece, June 29 - July 3, 2006. *Endothelium 13: 297, 2006.*
59. Hatziapostolou M, Polytarchou C, **Papadimitriou E**. FGF-2 stimulates LNCaP cell functions through heparin affin regulatory peptide up-regulation. *8th International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Corfu, Greece, June 29 - July 3, 2006. *Endothelium 13: 309, 2006.*
60. Drosou G, Mikelis C, **Papadimitriou E**. Role of heparin affin regulatory peptide in angiogenesis *in vivo*. *8th International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Corfu, Greece, June 29 - July 3, 2006. *Endothelium 13: 311, 2006.*
61. Poimenidi E, Hatziapostolou M, **Papadimitriou E**. Regulation of the expression of heparin affin regulatory peptide by serum in human endothelial and glioma cells. *8th International Conference "Angiogenesis: Basic Science and Clinical Applications"*, Corfu, Greece, June 29 - July 3, 2006. *Endothelium 13: 311, 2006.*
62. Lampropoulou E, Lambrou M, Parthymou A, Koutsoumpa M, Mikelis C, Giannopoulou E, **Papadimitriou E**. Pleiotrophin as a new target for therapy of tumors. *32nd FEBS Congress*, Vienna, Austria, July 7-12, 2007. *FEBS J 274(Suppl 1): 160, 2007.*
63. Panagi Z, Bountouris P, **Papadimitriou E**, Skouroliakou M, Kalfarentzos F. Preliminary evaluation of preoperative and short-term (1 year) postoperative serum fat-soluble vitamin levels in super-obese patients undergoing a Roux-en-Y gastric bypass with biliopancreatic diversion (RYGBP/BPD) malabsortive operation. *5th Panhellenic Congress of Pharmacology*, Athens, Greece, May 23-25, 2008. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition 22: 264, 2008.*
64. Koutsoumpa M, Hatziapostolou M, Mikelis C, Papadimitriou E. The stimulatory effects of aprotinin on human endothelial and prostate cancer cells are mediated by pleiotrophin. *5th Panhellenic Congress of Pharmacology*, Athens, Greece, May 23-25, 2008. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition 22: 201-202, 2008.*
65. Mikelis C, **Papadimitriou E**. Novel mechanism that mediates the angiogenic properties of pleiotrophin through $\alpha_v\beta_3$. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. *FEBS J 275(Suppl 1): 314, 2008.*

66. Drosou G, Mikelis C, Theochari K, Vourtsis D, Giannopoulou E, Katsoris P, **Papadimitriou E**. Expression of pleiotrophin is essential for angiogenesis in vivo. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. *FEBS J* 275(Suppl 1): 317, 2008.
67. Tsirmoula S, **Papadimitriou E**. Reactive oxygen species mediate the stimulatory effect of pleiotrophin on human cell migration. *33rd FEBS Congress and 11th IUBMB Conference*, Athens, Greece, June 28-July 3, 2008. *FEBS J* 275(Suppl 1): 321, 2008.
68. **Papadimitriou E**, Mikelis C, Lampropoulou E, Koutsioumpa M, Theochari K, Tsirmoula S, Theodoropoulou C, Lamprou M, Sfaelou E, Vourtsis D, Mpountouris P. The role of the growth factor pleiotrophin and its receptors in tumor growth and angiogenesis. *8th International Conference of Anticancer Research*, Kos, Greece, October 17-22, 2008. *Anticancer Res* 28(5C): 3436, 2008.
69. Daletos G, Magafa V, Panagoulis A, Lamprou M, **Papadimitriou E**, Geronikaki A, Cordopatis P. Synthesis and biological evaluation of cyclic peptides of $\alpha_4\beta_1$ integrin antagonists. *14th Panhellenic Pharmaceutical Congress*, Athens, Greece, May 9-11, 2009. *Eur J Drug Metab Pharmacokinet* 34 special issue: 21-22, 2009.
70. Koutsioumpa M, **Papadimitriou E**. A role of nucleolin in the pleiotrophin-induced cell migration. *34th FEBS Congress*, Prague, Czech Republic, July 4-9, 2009. *FEBS J* 276(Suppl 1): 240, 2009.
71. Tsirmoula S, **Papadimitriou E**. Pleiotrophin increases intracellular ROS levels and cell migration through activation of $\alpha_v\beta_3$ integrin. *34th FEBS Congress*, Prague, Czech Republic, July 4-9, 2009. *FEBS J* 276(Suppl 1): 254, 2009.
72. Cordopatis P, Daletos G, Magafa V, Lamprou M, **Papadimitriou E**, Zoumpoulakis P, Zervou M, Assimomytis N, Geronikaki A. Synthesis, evaluation and conformational solution studies of cysteine-based $\alpha_4\beta_1$ integrin ligands. *7th Hellenic Forum on Bioactive Peptides*, Patras, Greece, May 16-17, 2010. *J Pept Sci* 16(S2): 159, 2010.
73. Theodoropoulou C, **Papadimitriou E**. Role of pleiotrophin and its receptor protein tyrosine phosphatase β/ζ in vascular endothelial growth factor-induced endothelial cell migration. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 24: 141, 2010.
74. Koutsioumpa M, Mikelis C, Kieffer N, Skandalis S, Hellman U, Petrou C, Magafa V, Cordopatis P, **Papadimitriou E**. Cell surface expression of nucleolin is maintained by $\alpha_v\beta_3$ integrin and is required for pleiotrophin-induced cell migration. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition*, 24: 161, 2010.
75. Lampropoulou E, Hatzia Apostolou M, Skandalis S, Tsihchlis PN, Hellman U, **Papadimitriou E**. Cyclin-dependent kinase 5 interacts with RPTP β/ζ and mediates pleiotrophin-induced endothelial cell migration. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 24: 165, 2010.
76. Tsirmoula S, Dimas K, Ravazoula P, **Papadimitriou E**. Role of pleiotrophin in human prostate cancer cell growth in vivo. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 24: 217, 2010.
77. Vourtsis D, Sadikoglou E, Theodorakopoulou O, Lampropoulou C, Magoulas G, Drinas D, Papaioannou D, Papadimitriou E. Effect of all-trans-retinoic acid and conjugate with spermine on human endothelial and prostate cancer cell growth in vitro and angiogenesis in vivo. *6th Panhellenic Congress of Pharmacology*, Heraklion, Crete, June 4-6, 2010. *Review of Clinical Pharmacology and Pharmacokinetics, International Edition* 24: 224, 2010.
78. **Papadimitriou E**, Koutsioumpa M, Mikelis C. The growth factor pleiotrophin induces migration of endothelial and tumour cells that express $\alpha_v\beta_3$ integrin and nucleolin on their cell surface. *16th World Congress of Basic and Clinical Pharmacology*, Copenhagen, Denmark, July 17-23, 2010. *Basic Clin Pharmacol Toxicol* 107(Suppl 1): 513, 2010.

79. Daletos G, Lamprou M, Zoumpoulakis P, Zervou M, Assimomytis NL, Geronikaki A, Papadimitriou E, Magafa V, Cordopatis P. Synthesis, evaluation and conformational solution studies of cysteine-based $\alpha_4\beta_1$ integrin ligands. *The 31st European Peptide Symposium*, Copenhagen, Denmark, September 5-9, 2010. *J Pept Sci* 16(S2): 159, 2010.
80. Frilligou E, **Papadimitriou E**, and Tselios T. Microwave-assisted solid-phase peptide synthesis of the domain 60-110 of human pleiotrophin (hPTN) with two disulfide bonds on CLTR-CL resin *The 31st European Peptide Symposium*, Copenhagen, Denmark, September 5-9, 2010. *J Pept Sci* 16(S2): 73, 2010.
81. Kaspiris A, Mikelis C, Khaldi L, Grivas T, Kouvaras I, Dangas S, Vasileiadis E, **Papadimitriou E**. Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta (RPTP β/ζ) in patients with osteoarthritis. *2010 World Congress on Osteoarthritis*, Brussels, Belgium, September 23-26, 2010. *Osteoarthritis Cartilage* 18(Suppl 2): S77, 2010.
82. Koutsoumpa M, Mikelis C, Kieffer N, Skandalis S, Hellman U, Petrou C, Magafa V, Cordopatis P, **Papadimitriou E**. Cell surface expression of nucleolin is stimulated by $\alpha_v\beta_3$ integrin activation and is required for pleiotrophin-induced cell migration. *4th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 2-4, 2011. *Angiogenesis* 14: 80, 2011.
83. Bountouris P, **Papadimitriou E**. Effect of anti-diabetic drug rosiglitazone in pleiotrophin-induced endothelial cell activation. *4th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 2-4, 2011. *Angiogenesis* 14: 87, 2011.
84. Kouroufexi A, Theophanous-Kitiri S, Polykarpou G, Leotsinidis M, Kardamakis D, **Papadimitriou E**. Use of granulocyte growth factor in an elderly population receiving chemotherapy and radiotherapy. *"Advances and perspectives in Geriatric Oncology"*, Athens, Greece, February 17-18, 2012. *Forum Clin Oncol Special Edition*: 15, 2012.
85. Kaspiris A, **Papadimitriou E**, Chronopoulos E, Vasiliadis E, Khaldi L, Kouvaras I, Lamprou M. Immunolocalization of the human metalloelastase MMP-12 in the cartilage and subchondral bone in osteoarthritis. *39th Annual Congress of ECTS*, Stockholm, Sweden, May 19-23, 2012. *Bone* 50(Suppl1): S185, 2012.
86. Giannopoulou E, Kotsirilou D, Nikolakopoulos A, **Papadimitriou E**, Makatsoris T, Kalofonos H. The impact of EGF on Notch protein levels in non-small cell lung cancer. *22nd Biennial Congress of the European Association for Cancer Research*, Barcelona, Spain, July 7-10, 2012. *Eur J Cancer* 48: S115, 2012.
87. Zervou M, Potamitis C, Zoumpoulakis P, Fotakis C, **Papadimitriou E**, Cordopatis P, Magafa V. Pharmacophore model of cysteine-based $\alpha_4\beta_1$ integrin ligands based on conformational solution studies. *32nd European Peptide Symposium*, Athens, Greece, September 2-7, 2012. *J Pept Sci* 18: S165, 2012.
88. **Papadimitriou E**, Koutsoumpa M, Poimenidi E, Theodoropoulou C, Kieffer N, Courty J. Angiogenic growth factor-induced cell surface expression of nucleolin and cell migration depend on $\alpha_v\beta_3$ integrin expression. *22nd European Tissue Repair Society Meeting*, Athens, Greece, October 4-5, 2012. *Wound Repair Regen* 20(5): A105, 2012.
89. Nikolakopoulos A, Kotsirilou D, Giannopoulou E, **Papadimitriou E**, Makatsoris T, Kalofonos, HP. Inhibition of Notch pathway in non-small cell lung cancer. *11th International Congress on Targeted Anticancer Therapies (TAT 2013)*, Paris, France, March 4-6, 2013. *Ann Oncol* 24(Suppl 1): i21-i22, 2013.
90. Lamprou M, Sarigiannis Y, Bakandritsos A, Avgoustakis K, Winnefeld F, Pispas S, Meristoudi A, Zboril R, **Papadimitriou E**. Effects of poly(methacrylic acid)-graft-poly(ethylene glycol) coated magnetic nanoparticles on drug delivery to endothelial and cancer cells. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14, 2014. *Angiogenesis* 17(3): 758, 2014.

91. Lamprou M, **Papadimitriou E.** Putative role of vascular endothelial growth factor receptor 2 in pleiotrophin-induced endothelial cell migration. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14, 2014. *Angiogenesis* 17(3): 752, 2014.
92. Koutsioumpa M, Poimenidi E, Theodoropoulou C, Pantazaka E, Skoura A, Megalooikonomou V, Kieffer N, Courty J, Sugahara K, **Papadimitriou E.** A role of receptor protein tyrosine phosphatase beta/zeta in vascular endothelial growth factor-induced endothelial cell migration. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14, 2014. *Angiogenesis* 17(3): 754, 2014.
93. Poimenidi E, Theodoropoulou C, Koutsioumpa M, van den Broek M, Koolwijk P, **Papadimitriou E.** VEGF decreases expression and secretion of pleiotrophin in a receptor protein tyrosine phosphatase beta/zeta and cell surface nucleolin-dependent manner. *5th International Meeting on Angiogenesis*, Amsterdam, The Netherlands, March 12-14, 2014. *Angiogenesis* 17(3): 754, 2014.
94. Lampropoulou E, Logoviti I, Koutsioumpa M, **Papadimitriou E.** Cyclin-dependent kinase 5 is involved in pleiotrophin-induced endothelial cell migration. *40th FEBS Congress, The Biochemical Basis of Life, Berlin, Germany*, July 4-9, 2015. *FEBS J* 282(Suppl 1): 221, 2015.
95. Lamprou M, Sarigiannis Y, Bakandritsos A, Avgoustakis K, Winnefeld F, Pispas S, Meristoudi A, **Papadimitriou E.** Drug delivery to human endothelial and glioblastoma cells by poly(methacrylic acid)-graft-poly(ethylene glycol)-coated magnetic nanoparticles. *40th FEBS Congress, The Biochemical Basis of Life, Berlin, Germany*, July 4-9, 2015. *FEBS J* 282(Suppl 1): 266, 2015.
96. Pantazaka E, Castana P, Tassopoulos D, Poimenidi E, **Papadimitriou E.** The role of receptor protein tyrosine phosphatase beta/zeta in cell migration. *37th SEF National Meeting with guest Society: The British Pharmacological Society, Barcelona, Spain*, June 18-21, 2017. *Basic Clin Pharmacol Toxicol* 121(Suppl 2): 66, 2017.
97. Tsirmoula S, Skondra L, Enake M, Koutsioumpa M, Kastana P, Mikelis CM, Skandalis S, Hellman U, Sugahara K, **Papadimitriou E.** Interaction of moesin with $\alpha_v\beta_3$ integrin regulates endothelial cell migration. *3rd Joint Meeting of the European Society for Microcirculation (ESM) and the European Vascular Biology Organization (EVBO)*, Maastricht, The Netherlands, April 15-18, 2019. *J Vasc Res* 56(Suppl 1): 89, 2019.
98. Lamprou M, Kastana P, Choleva E, Kofina F, Tzoupis H, Pantazaka E, Sajib MS, Tselios T, Mikelis CM, **Papadimitriou E.** Binding of pleiotrophin to vascular endothelial growth factor receptor 2 regulates endothelial cell migration. *44th FEBS Congress, Krakow, Poland, July 6-11, 2019.* *FEBS Open Bio* 9: P-06-031, 2019.

Abstracts in conference proceedings

International Conferences: 75

Greek Conferences: 94

CURRENT TEACHING ACTIVITIES

Undergraduate courses:

- Pharmacology I and II
- Molecular Pharmacology
- Introduction to Pharmaceutical Sciences

Postgraduate courses:

- Molecular Targets of Drug Action
- Preclinical and Clinical Evaluation of Medicines
- Precision Therapeutic Approaches
- Molecular Pharmacology-Immunology (Department of Chemistry, University of Patras)

Supervisor:

3 postdoctoral fellows (2 completed)

15 PhD theses (9 completed, 3 to complete by summer 2020)

50 MSc theses (45 completed)

31 final year pre-graduate Experimental Theses (28 completed, 3 in progress)

33 final year pre-graduate Literature Theses

Present academic/professional appointments of former PhD students/post-docs:

Efstathia Giannopoulou: Investigator Initiated Study Specialist, Zeincro, Athens.

Apostolos Polykratis: Postdoctoral fellow at University of Cologne, CECAD Research Center, Germany

Anastassia Parthymou: Research Assistant, Endocrinology Lab, Dept of Medicine, University of Patras, Greece.

Christos Polytarchou: Reader in Health and Disease, Interdisciplinary Biomedical Research Centre, School of Science and Technology, Nottingham Trent University, UK.

Maria Hatziapostolou: Group Leader in Epigenetics of Diseases, Senior Independent Research Fellow, Biosciences, School of Science and Technology, Nottingham Trent University, UK.

Constantinos Mikelis: Assistant Professor, Biomedical Sciences Department, School of Pharmacy, Texas Tech University, USA

Evgenia Lampropoulou: Specializes as a pediatrician at the "Agia Sofia" Pediatric Hospital, Athens, Greece.

Marina Koutsoumpa: Postdoctoral fellow at UCLA, USA and Vice President of Cancer Biology, KYNAN Pharma, USA.

Sotiria Tsirmoula: Hospital pharmacist.

Evangelia Poimenidi: Department of Critical Care, King's College Hospital NHS Foundation Trust, London, United Kingdom.

Margarita Lamprou: Postdoctoral fellow at Dept of Pharmacy, University of Patras, Greece.

BOOKS/TEACHING MATERIAL

“**Angiogenesis: Basic Science and Clinical Applications**”, Editor (co-editor with emeritus Professor Dr. M.E. Maragoudakis), Transworld Research Network, ISBN: 978-81-7895-302-1, 2007.

“**Molecular Pharmacology**”, author, Parisianou A.E., Athens, Greece, ISBN: 978-960-394-609-0, 2010.

“**General Principles in Pharmacology**”, author, University of Patras, 1999, 2001.

“**Laboratory of Molecular Pharmacology**” notes, author, University of Patras, 2000, 2001, 2003, 2005, 2008.

“**Introduction to Pharmaceutical Sciences**” notes, University of Patras, 2008 (co-author with C. Avgoustakis and G. Pairas).

“**Lecture Notes: Clinical Pharmacology and Therapeutics**” by Gerald A. McKay, John L. Reid and Matthew R. Walters (translated and edited in Greek, Parisianou A.E., Athens, Greece, ISBN: 978-960-394-980-0, 2014).

“**Pharmacology, 7th Edition**” by Humphry P. Rang, Maureen M. Dale, James M. Ritter, Rod Flower and Graeme Henderson (participation in translation and Greek edition, Parisianou A.E., Athens, Greece, ISBN: 960-394-923-X, 2014).

“**Pharmacology, 8th Edition**” by Humphry P. Rang, Maureen M. Dale, James M. Ritter, Rod Flower and Graeme Henderson (participation in translation and Greek edition, Parisianou A.E., Athens, Greece, ISBN: 978-960-583-173-8, 2018).

“**Remington: An Introduction to Pharmacy**” by Loyd V. Allen (participation in translation and Greek edition, Parisianou A.E., Athens, Greece, ISBN: 978-0-85711-104-3, 2019).

INTERNATIONAL COLLABORATORS

- Dr. *Jose Courty*, at Universite Paris 12 Val de Marne, Paris, France.
- Dr. *Pieter Koolwijk*, at VU University Medical Centre, Amsterdam, The Netherlands.
- Dr. *Nelly Kieffer* at Jiao Tong University Medical School, Shanghai, China.
- Dr. *Christos Polytarchou* at Interdisciplinary Biomedical Research Centre, School of Science and Technology, Nottingham Trent University, UK.
- Dr. *Maria Hatzia Apostolou* at Nottingham Trent University, UK.
- Dr. *Kazuyuki Sugahara*, at Hokkaido University Graduate School of Life Sciences, Kita-ku, Sapporo, Japan.
- Dr. *Peter Giannoudis*, Academic Unit of Orthopaedic and Trauma Surgery, University of Leeds, UK.
- Dr. *Constantinos Mikelis* at Biomedical Sciences Department, School of Pharmacy, Texas Tech University, USA.
- Dr. *Gonzalo Herradon*, Associate Professor of Pharmacology, Faculty of Pharmacy at the University CEU San Pablo in Madrid, Spain.